ストックスクリーナーアプリを入手
48.59
3.71%
-1.87
プレマーケット:
48.45
-0.14
-0.29%
前日終値:
$50.46
開ける：
$50.07
24時間の取引高:
908.09K
Relative Volume:
0.87
時価総額：
$3.44B
収益：
-
当期純損益:
$-141.43M
株価収益率:
-19.77
EPS:
-2.4581
ネットキャッシュフロー:
$-226.41M
1週間 パフォーマンス:
-9.60%
1か月 パフォーマンス:
-26.99%
6か月 パフォーマンス:
+106.06%
1年 パフォーマンス:
+122.18%
1日の値動き範囲:
$47.71
$50.40
1週間の範囲:
$47.71
$61.20
52週間の値動き範囲:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(650) 457-1978
住所
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ALNY, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
48.59 | 3.44B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges - AOL.com
B Group Acquires 4.62% Portfolio Stake in Structure Therapeutics | 2025 InvestmentNews and Statistics - IndexBox
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Did Positive Phase 2 Aleniglipron Data Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics’ Stock Climbing Amid 44-Week Trial Data Buzz - StocksToTrade
William Blair reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Structure Therapeutics ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) Stock Surges 10% as GLP-1 Pill Outperforms Lilly and Novo - CoinCentral
Leerink reiterates Outperform on Structure Therapeutics stock - Investing.com
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results - TipRanks
Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Bitget
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
HighVista Strategies LLC Acquires 149,615 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
First Light Asset Management LLC Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Casdin Capital LLC - MarketBeat
Baker BROS. Advisors LP Sells 952,658 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation After Its Quarterly Profit Turnaround - Sahm
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf RegistrationAnd What's Next - Sahm
Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail
Tax withholding trims Structure Therapeutics (NASDAQ: GPCR) CMO stake - Stock Titan
Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes - Stock Titan
Structure Therapeutics (GPCR) CFO logs tax-withholding share disposition - Stock Titan
Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions - Stock Titan
Structure Therapeutics (GPCR) CEO reports tax share withholding and large trust-held stake - Stock Titan
HC Wainwright Issues Negative Estimate for GPCR Earnings - MarketBeat
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - TradingView
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
大文字化:
|
ボリューム (24 時間):